Next 10 |
home / stock / glue / glue articles
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel m...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel mo...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel mo...
BOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing n...
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter...
Wedbush initiated coverage on Monte Rosa Therapeutics Inc (NASDAQ:GLUE), a company focused on developing molecular glue degraders (M...
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecul...
U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fe...
Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024 Received US FDA Fast...
News, Short Squeeze, Breakout and More Instantly...
Monte Rosa Therapeutics Inc. Company Name:
GLUE Stock Symbol:
NASDAQ Market:
Monte Rosa Therapeutics Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside cha...
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 202...
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected ...